← Back to Search

Normal Cognition (NC) with at least 1 vascular risk factor for Dementia (MarkVCID Trial)

N/A
Recruiting
Led By Steven M. Greenberg, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline.
Awards & highlights

MarkVCID Trial Summary

Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.

Eligible Conditions
  • Dementia
  • Cognitive Impairment

MarkVCID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
SVD progression as measured by decline in global cognition
Secondary outcome measures
SVD progression as measured by decline in executive function

MarkVCID Trial Design

4Treatment groups
Experimental Treatment
Group I: Subjective Cognitive Decline (SCD)Experimental Treatment1 Intervention
Subjective cognitive decline is defined as: Cognitive concerns based on a Short eCog-12 score ≥ 3 (based on administration to participant), AND Normal cognition (neuropsychological testing within normal range).
Group II: Normal Cognition (NC) with at least 1 vascular risk factorExperimental Treatment1 Intervention
NC is defined as: No diagnosis of SCD, MCI, or dementia; AND CDR: Sum of Boxes = 0 AND neuropsychological testing in normal range. Participants must have at least 1 of the following criteria prior to enrollment: Diabetes (at least 1): Fasting (8-hour) blood sugar ≥126 mg/dL Random or Post-prandial blood sugar ≥200 mg/dL HbA1C ≥6.5% Treatment with anti-diabetic medicine Hypertension plus (at least 2): Use of anti-hypertensive medications for lowering blood pressure for ≥10 years Current use of 2 or more anti-hypertensive meds for lowering blood pressure Blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90 Second blood pressure reading in a research or clinical setting in the last 2 years (different date) with SBP ≥140 or DBP ≥90 Evidence of likely HTN end organ damage MRI factors (at least 1): Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥2 ≥1 microbleeds ≥1 lacunar infarcts
Group III: Mild DementiaExperimental Treatment1 Intervention
Mild dementia is defined as: The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria: Interfere with ability to function as before at work or at usual activities? Represent a decline from previous levels of functioning? Are not explained by delirium or major psychiatric disorder? AND Impairment in one* or more of the following domains. Impaired ability to acquire and remember new information. Impaired reasoning and handling of complex tasks, poor judgment. Impaired visuospatial abilities. Impaired language functions. Changes in personality, behavior, or comportment * In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, posterior cortical atrophy), the subject must not fulfill criteria for MCI. AND CDR: Global Score = 0.5 or 1
Group IV: Mild Cognitive Impairment (MCI)Experimental Treatment1 Intervention
Mild cognitive impairment is defined as: There is a cognitive concern, i.e., the subject, the co-participant, or a clinician is concerned about a change in cognition compared to the subject's previous level. There is impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills) that is greater than would be expected for the patient's age and educational background. There is largely preserved independence in functional abilities (no change from prior level of functioning or requires only extra effort and minimal aids or assistance). There is no evidence of dementia (cognitive changes are mild and there is no evidence of a significant impairment in social or occupational functioning).

Find a Location

Who is running the clinical trial?

University of KentuckyOTHER
185 Previous Clinical Trials
224,842 Total Patients Enrolled
University of California, Los AngelesOTHER
1,528 Previous Clinical Trials
10,275,051 Total Patients Enrolled
13 Trials studying Dementia
5,550 Patients Enrolled for Dementia
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
878,214 Total Patients Enrolled
1 Trials studying Dementia
144 Patients Enrolled for Dementia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Steven M. Greenberg, MD,PhD 2021. "Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06284213.
All > Pflugerville Tx > Milwaukee
~991 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top